ACER Acer Therapeutics Inc

Price (delayed)

$2.56

Market cap

$36.63M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.35

Enterprise value

$14.51M

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer's pipeline includes four programs: ...

Highlights
ACER's EPS is up by 35% YoY and by 20% from the previous quarter
The company's net income rose by 20% YoY and by 13% QoQ
The company's quick ratio has shrunk by 64% YoY and by 9% QoQ
Acer Therapeutics's equity has decreased by 31% YoY and by 25% from the previous quarter

Key stats

What are the main financial stats of ACER
Market
Shares outstanding
14.31M
Market cap
$36.63M
Enterprise value
$14.51M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.71
Price to sales (P/S)
9.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.63
Earnings
Revenue
$4M
EBIT
-$17.44M
EBITDA
-$17.37M
Free cash flow
$889,753
Per share
EPS
-$1.35
Free cash flow per share
$0.06
Book value per share
$0.54
Revenue per share
$0.28
TBVPS
$2.26
Balance sheet
Total assets
$39.98M
Total liabilities
$32.21M
Debt
$0
Equity
$7.78M
Working capital
-$255,529
Liquidity
Debt to equity
0
Current ratio
0.99
Quick ratio
0.69
Net debt/EBITDA
1.27
Margins
EBITDA margin
-434.5%
Gross margin
100%
Net margin
-422.9%
Operating margin
-434.5%
Efficiency
Return on assets
-59.1%
Return on equity
-183.2%
Return on invested capital
N/A
Return on capital employed
-224.2%
Return on sales
-436.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACER stock price

How has the Acer Therapeutics stock price performed over time
Intraday
0%
1 week
1.59%
1 month
0.79%
1 year
0.79%
YTD
-2.29%
QTD
-10.49%

Financial performance

How have Acer Therapeutics's revenue and profit performed over time
Revenue
$4M
Gross profit
$4M
Operating income
-$17.37M
Net income
-$16.91M
Gross margin
100%
Net margin
-422.9%
The company's net income rose by 20% YoY and by 13% QoQ
The company's operating income rose by 18% YoY and by 10% QoQ
Acer Therapeutics's net margin has increased by 13% QoQ
ACER's operating margin is up by 10% from the previous quarter

Growth

What is Acer Therapeutics's growth rate over time

Valuation

What is Acer Therapeutics stock price valuation
P/E
N/A
P/B
4.71
P/S
9.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.63
ACER's EPS is up by 35% YoY and by 20% from the previous quarter
Acer Therapeutics's equity has decreased by 31% YoY and by 25% from the previous quarter
ACER's price to book (P/B) is 15% higher than its 5-year quarterly average of 4.1 and 12% higher than its last 4 quarters average of 4.2

Efficiency

How efficient is Acer Therapeutics business performance
Acer Therapeutics's return on assets has increased by 45% YoY and by 32% QoQ
Acer Therapeutics's ROE has decreased by 44% YoY but it has increased by 5% from the previous quarter
ACER's ROS is up by 10% from the previous quarter

Dividends

What is ACER's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACER.

Financial health

How did Acer Therapeutics financials performed over time
Acer Therapeutics's total assets is 24% higher than its total liabilities
Acer Therapeutics's total assets has surged by 170% YoY but it has decreased by 10% QoQ
The company's quick ratio has shrunk by 64% YoY and by 9% QoQ
Acer Therapeutics's debt is 100% lower than its equity
Acer Therapeutics's equity has decreased by 31% YoY and by 25% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.